Damora Therapeutics (DMRA) Depreciation & Amortization (CF) (2021 - 2026)
Damora Therapeutics (DMRA) posted Depreciation & Amortization (CF) of $5000.0 for Q1 2026, down 16.67% on a QoQ basis from $6000.0 in Q4 2025, and little changed year-over-year from $5000.0 in Q1 2025.
Damora Therapeutics (DMRA) Depreciation & Amortization (CF) (2021 - 2026) Analysis & Trends
Damora Therapeutics' Depreciation & Amortization (CF) history runs 6 years deep, the most recent figure standing at $5000.0 for Q1 2026.
- Quarterly Depreciation & Amortization (CF) changed 0.0% year-over-year to $5000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $23000.0 (up 9.52% YoY) and the FY2025 annual result came in at $22000.0, up 4.76% from the prior year.
- Depreciation & Amortization (CF) was $5000.0 for Q1 2026 at Damora Therapeutics, down from $6000.0 in the prior quarter.
- Across five years, Depreciation & Amortization (CF) topped out at $211000.0 in Q3 2023 and bottomed at $5000.0 in Q1 2024.
- A 5-year average of $23000.0 and a median of $6000.0 in 2022 frame the typical range for Depreciation & Amortization (CF).
- Annual changes were most pronounced in 2023 — Depreciation & Amortization (CF) jumped 3416.67% — and 2024, when it plunged 97.16%.
- Damora Therapeutics' Depreciation & Amortization (CF) stood at $21000.0 in 2022, then jumped by 157.14% to $54000.0 in 2023, then sank by 90.74% to $5000.0 in 2024, then advanced by 20.0% to $6000.0 in 2025, then decreased by 16.67% to $5000.0 in 2026.
- Business Quant data shows DMRA's Depreciation & Amortization (CF) at $5000.0 in Q1 2026, $6000.0 in Q4 2025, and $6000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 196,658.72 |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 41.14 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 91,781.47 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 55.90 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 123.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 2.20 Mn |
| 10 | Damora Therapeutics | 1.00 Bn | 798.11 Mn | - | 5,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 5,000.00 |
| Mar 31, 2026 | 5,000.00 |
| Dec 31, 2025 | 6,000.00 |
| Dec 31, 2025 | 6,000.00 |
| Sep 30, 2025 | 6,000.00 |
| Sep 30, 2025 | 6,000.00 |
| Jun 30, 2025 | 6,000.00 |
| Jun 30, 2025 | 6,000.00 |
| Mar 31, 2025 | 5,000.00 |
| Mar 31, 2025 | 5,000.00 |
| Dec 31, 2024 | 5,000.00 |
| Dec 31, 2024 | 5,000.00 |
| Sep 30, 2024 | 6,000.00 |
| Sep 30, 2024 | 6,000.00 |
| Jun 30, 2024 | 5,000.00 |
| Jun 30, 2024 | 5,000.00 |
| Mar 31, 2024 | 5,000.00 |
| Mar 31, 2024 | 5,000.00 |
| Dec 31, 2023 | 54,000.00 |
| Dec 31, 2023 | 54,000.00 |